MADCAM1 and graft versus host disease: Similarly, MAdCAM-1 deficiency on recipients reduced GVHD in mice (41), moreover, administration of anti-MAdCAM-1 antibody reduced GVHD without impairing GVL effects in both nonirradiated recipients and in recipients treated with myeloablative conditioning (45).